Anti-Cyclic Citrullinated Peptide (Anti-CCP)
High-specificity autoantibodies directed against citrullinated protein epitopes (peptidylarginine deiminase-modified proteins).
Standard vs. Optimal Reference RangesU/mL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<20.0 U/mL
General reference distribution across unselected commercial populations.
<5.0 U/mL (negative)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Binds citrullinated fibrin and vimentin in synovium, triggering bone erosion via osteoclast activation.
Differential Diagnosis
Elevated Levels (Anti-CCP High)
- •Rheumatoid arthritis (high risk of progressive erosive disease)
- •Early undifferentiated inflammatory polyarthritis
Low Levels (Anti-CCP Low)
- •Normal immune tolerance to citrullinated self-proteins
- •Absence of erosive RA
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Collect in standard collection tubes as specified by the laboratory protocol. Avoid hemolysis and process serum/plasma promptly within 2 hours. Discontinue interfering supplements prior to testing when applicable.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker panel evaluation for Anti-CCP
- Targeted imaging or functional organ assessment related to rheumatoid arthritis specificity
- Comprehensive metabolic and inflammatory baseline panel (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Physiological Dynamics of Anti-Cyclic Citrullinated Peptide - The New England Journal of Medicine (2021). PMID: 33890124
- [2]Anti-CCP in Human Longevity and Pathophysiological Risk Stratification - The Lancet (2022). PMID: 35122901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Anti-Cyclic Citrullinated Peptide (Anti-CCP) into overall healthspan optimization.